Evidence map›Paper›PMID 25631792›Full record

ArticleJournal of clinical microbiology2015

Evaluation of the boson chemiluminescence immunoassay as a first-line screening test in the ECDC algorithm for syphilis serodiagnosis in a population with a high prevalence of syphilis.

Xin-Hui Qiu, Ya-Feng Zhang, Yu-Yan Chen, Qiao Zhang, Fu-Yi Chen, Long Liu, Jin-Yi Fan, Kun Gao, Xiao-Zhen Zhu, Wei-Hong Zheng and 7 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Laboratory Diagnostic Tools for Syphilis: Current Status and Future Prospects.Frontiers in cellular and infection microbiology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 2 countries.

Xin-Hui QiuZhongshan Hospital, Medical College of Xiamen University, Xiamen, China.
Ya-Feng ZhangZhongshan Hospital, Medical College of Xiamen University, Xiamen, China.
Yu-Yan ChenZhongshan Hospital, Medical College of Xiamen University, Xiamen, China.
Qiao ZhangZhongshan Hospital, Medical College of Xiamen University, Xiamen, China.
Fu-Yi ChenDepartment of Physiology and Neurobiology, University of Connecticut, Storrs, Connecticut, USA.
Long LiuDepartment of Chemistry and Biology, College of Science, National University of Defense and Technology, Changsha, China.
Jin-Yi FanZhongshan Hospital, Medical College of Xiamen University, Xiamen, China.
Kun GaoZhongshan Hospital, Medical College of Xiamen University, Xiamen, China.
Xiao-Zhen ZhuZhongshan Hospital, Medical College of Xiamen University, Xiamen, China.
Wei-Hong ZhengZhongshan Hospital, Medical College of Xiamen University, Xiamen, China.
Hui-Lin ZhangZhongshan Hospital, Medical College of Xiamen University, Xiamen, China.
Li-Rong LinZhongshan Hospital, Medical College of Xiamen University, Xiamen, China.
Li-Li LiuZhongshan Hospital, Medical College of Xiamen University, Xiamen, China.
Man-Li TongZhongshan Hospital, Medical College of Xiamen University, Xiamen, China.
Chang-Gong ZhangBoson Biotechnology Co., Ltd., Xiamen, Xiamen, China.
Jian-Jun NiuZhongshan Hospital, Medical College of Xiamen University, Xiamen, China niujianjun211@xmu.edu.cn yangtianci@xmu.edu.cn.
Tian-Ci YangZhongshan Hospital, Medical College of Xiamen University, Xiamen, China ShenZhen Research Institute of Xiamen University, ShenZhen, China niujianjun211@xmu.edu.cn yangtianci@xmu.edu.cn.
Zhongshan Hospital of Xiamen University · CNUniversity of Connecticut · USXiamen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We developed a new Boson chemiluminescence immunoassay (CIA) and evaluated its application with cross-sectional analyses. Our results indicated that the Boson CIA demonstrated strong discriminatory power in diagnosing syphilis and that it can be used as a first-line screening test for syphilis serodiagnosis using the European Centre for Disease Prevention and Control algorithm or as a confirmatory test when combined with a patient's clinical history.

Indexed as

AlgorithmsChinaHumansLuminescent MeasurementsSensitivity and SpecificitySyphilis

Identifiers

PMID25631792
PMCPMC4365203
OpenAlexW2010490498

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.